DE60215132T2 - Acylierte piperidin-derivate als melanocortin-4-rezeptor-agonisten - Google Patents
Acylierte piperidin-derivate als melanocortin-4-rezeptor-agonisten Download PDFInfo
- Publication number
- DE60215132T2 DE60215132T2 DE60215132T DE60215132T DE60215132T2 DE 60215132 T2 DE60215132 T2 DE 60215132T2 DE 60215132 T DE60215132 T DE 60215132T DE 60215132 T DE60215132 T DE 60215132T DE 60215132 T2 DE60215132 T2 DE 60215132T2
- Authority
- DE
- Germany
- Prior art keywords
- alkyl
- phenyl
- independently selected
- heteroaryl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 C*(C1)N(*)C[C@@](*)[C@@]1(*)C(N1CCC(*)(*)CC1)=O Chemical compound C*(C1)N(*)C[C@@](*)[C@@]1(*)C(N1CCC(*)(*)CC1)=O 0.000 description 7
- KNBARVOBYLRMMT-DCWQJPKNSA-N CCN(CC[C@H]1C(N(CC2)CCC2(C2CCCCC2)C(NC(C)(C)C)=O)=O)CC1c(cc1)ccc1F Chemical compound CCN(CC[C@H]1C(N(CC2)CCC2(C2CCCCC2)C(NC(C)(C)C)=O)=O)CC1c(cc1)ccc1F KNBARVOBYLRMMT-DCWQJPKNSA-N 0.000 description 2
- MCTADDXBWAMMJL-DCWQJPKNSA-N CC(C)(CO1)N(CC(CC2)(CCN2C([C@H](CCN(C)C2)C2c(cc2)ccc2Cl)=O)C2CCCCC2)C1=O Chemical compound CC(C)(CO1)N(CC(CC2)(CCN2C([C@H](CCN(C)C2)C2c(cc2)ccc2Cl)=O)C2CCCCC2)C1=O MCTADDXBWAMMJL-DCWQJPKNSA-N 0.000 description 1
- GZQUOGPCEWEENG-UHFFFAOYSA-N CC(C)N(CC1C(N(CC2)CCC2(CN(C(C)(C)CO2)C2=O)C2CCCCC2)=O)CC1c(c(F)c1)ccc1F Chemical compound CC(C)N(CC1C(N(CC2)CCC2(CN(C(C)(C)CO2)C2=O)C2CCCCC2)=O)CC1c(c(F)c1)ccc1F GZQUOGPCEWEENG-UHFFFAOYSA-N 0.000 description 1
- VWFHLCARTPZBHX-ONJSCSTBSA-N CC(C)N(CC1[C@@H](N(CC2)CCC2(C2CCCCC2)C(NC(C)(C)C)=O)O)CC1c(c(F)c1)ccc1F Chemical compound CC(C)N(CC1[C@@H](N(CC2)CCC2(C2CCCCC2)C(NC(C)(C)C)=O)O)CC1c(c(F)c1)ccc1F VWFHLCARTPZBHX-ONJSCSTBSA-N 0.000 description 1
- VSIFOQCHGOPMQB-GEVKEYJPSA-N CC(C)N(CCC1C(N(CC2)CCC2(C2CCCCC2)C(NC(C)(C)C)=O)=O)C[C@H]1c(cc1)ccc1F Chemical compound CC(C)N(CCC1C(N(CC2)CCC2(C2CCCCC2)C(NC(C)(C)C)=O)=O)C[C@H]1c(cc1)ccc1F VSIFOQCHGOPMQB-GEVKEYJPSA-N 0.000 description 1
- GZQUOGPCEWEENG-FXDYGKIASA-N CC(C)N(C[C@H]1C(N(CC2)CCC2(CN(C(C)(C)CO2)C2=O)C2CCCCC2)=O)CC1c(c(F)c1)ccc1F Chemical compound CC(C)N(C[C@H]1C(N(CC2)CCC2(CN(C(C)(C)CO2)C2=O)C2CCCCC2)=O)CC1c(c(F)c1)ccc1F GZQUOGPCEWEENG-FXDYGKIASA-N 0.000 description 1
- HSKFWUNQSAWFDR-UHFFFAOYSA-N CC(CO1)N(C)C1=O Chemical compound CC(CO1)N(C)C1=O HSKFWUNQSAWFDR-UHFFFAOYSA-N 0.000 description 1
- KYRDJBPOBQOPNY-UHFFFAOYSA-N CCN(CCC1C(N(CC2)CCC2(CN(C(C)(C)CO2)C2=O)C2CCCCC2)=O)CC1c(cc1)ccc1F Chemical compound CCN(CCC1C(N(CC2)CCC2(CN(C(C)(C)CO2)C2=O)C2CCCCC2)=O)CC1c(cc1)ccc1F KYRDJBPOBQOPNY-UHFFFAOYSA-N 0.000 description 1
- SVSWYHCUSYVBHW-UHFFFAOYSA-N CN(C1(CC1)CO1)C1=O Chemical compound CN(C1(CC1)CO1)C1=O SVSWYHCUSYVBHW-UHFFFAOYSA-N 0.000 description 1
- QWEXMZQMVVAVQB-UHFFFAOYSA-N CN(C1(CCCC1)CO1)C1=O Chemical compound CN(C1(CCCC1)CO1)C1=O QWEXMZQMVVAVQB-UHFFFAOYSA-N 0.000 description 1
- HWHNFJYQDMSYAF-UHFFFAOYSA-N Cc1nnn[n]1C Chemical compound Cc1nnn[n]1C HWHNFJYQDMSYAF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27225801P | 2001-02-28 | 2001-02-28 | |
| US272258P | 2001-02-28 | ||
| US30057201P | 2001-06-22 | 2001-06-22 | |
| US300572P | 2001-06-22 | ||
| PCT/US2002/005623 WO2002068387A2 (en) | 2001-02-28 | 2002-02-25 | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60215132D1 DE60215132D1 (de) | 2006-11-16 |
| DE60215132T2 true DE60215132T2 (de) | 2007-08-23 |
Family
ID=26955403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60215132T Expired - Lifetime DE60215132T2 (de) | 2001-02-28 | 2002-02-25 | Acylierte piperidin-derivate als melanocortin-4-rezeptor-agonisten |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7015235B2 (enExample) |
| EP (1) | EP1372653B1 (enExample) |
| JP (1) | JP4323169B2 (enExample) |
| AT (1) | ATE341327T1 (enExample) |
| AU (1) | AU2002255597B8 (enExample) |
| CA (1) | CA2439149C (enExample) |
| DE (1) | DE60215132T2 (enExample) |
| ES (1) | ES2272703T3 (enExample) |
| WO (1) | WO2002068387A2 (enExample) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030076716A (ko) | 2001-02-28 | 2003-09-26 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 효능제로서 아실화 피페리딘 유도체 |
| CA2439119A1 (en) | 2001-02-28 | 2002-09-06 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| US6911447B2 (en) | 2001-04-25 | 2005-06-28 | The Procter & Gamble Company | Melanocortin receptor ligands |
| CA2453609C (en) | 2001-07-18 | 2010-05-04 | Merck & Co., Inc. | Bridged piperidine derivatives as melanocortin receptor agonists |
| US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
| US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
| JP2005504043A (ja) | 2001-08-10 | 2005-02-10 | パラチン テクノロジーズ インク． | 生物学的に活性な金属ペプチド類のペプチド模倣体類 |
| US7354923B2 (en) | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
| US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| US7026335B2 (en) | 2002-04-30 | 2006-04-11 | The Procter & Gamble Co. | Melanocortin receptor ligands |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| CA2498272A1 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Piperazine urea derivatives as melanocortin-4 receptor agonists |
| TW200504033A (en) | 2002-10-23 | 2005-02-01 | Procter & Gamble | Melanocortin receptor ligands |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2004078717A1 (en) * | 2003-03-03 | 2004-09-16 | Merck & Co., Inc. | Acylated piperazine derivatives as melanocortin-4 receptor agonists |
| US6998488B2 (en) | 2003-03-10 | 2006-02-14 | Merck & Co., Inc. | Process and intermediates for the preparation of 4-aryl piperidines |
| AU2004226452B2 (en) * | 2003-03-26 | 2008-07-24 | Merck Sharp & Dohme Corp. | Bicyclic piperidine derivatives as melanocortin-4 receptor agonists |
| BRPI0409078A (pt) | 2003-04-04 | 2006-04-18 | Merck & Co Inc | composto, métodos para o tratamento ou prevenção de distúrbios, doenças ou condições responsivas à ativação do receptor de melanocortina-4, para o tratamento ou prevenção de obesidade, para o tratamento ou prevenção de um distúrbio relacionado com a obesidade, para o tratamento ou prevenção de diabete melito, para o tratamento ou prevenção da disfunção sexual masculina ou feminina e para o tratamento ou prevenção de disfunção erétil, composição farmacêutica, métodos para o tratamento de disfução erétil em um mamìfero, para o tratamento de diabete em um mamìfero e para o tratamento de obesidade em um mamìfero, e, uso de um composto |
| AR044510A1 (es) * | 2003-04-14 | 2005-09-14 | Merck & Co Inc | Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina |
| US7049323B2 (en) | 2003-04-25 | 2006-05-23 | Bristol-Myers Squibb Company | Amidoheterocycles as modulators of the melanocortin-4 receptor |
| CN1826116A (zh) | 2003-07-22 | 2006-08-30 | 麦克公司 | 作为黑皮素－4受体激动剂的哌啶衍生物 |
| CA2551037A1 (en) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
| GB0402492D0 (en) * | 2004-02-04 | 2004-03-10 | Pfizer Ltd | Pharmaceutically active compounds |
| US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
| EP1765889B1 (en) * | 2004-03-02 | 2016-03-30 | Bridgestone Corporation | Bulk polymerization process |
| WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
| US7618987B2 (en) | 2004-07-19 | 2009-11-17 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin 4-receptor agonists |
| CA2584806C (en) | 2004-11-01 | 2014-06-17 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
| GB0428514D0 (en) * | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| ES2574014T3 (es) | 2005-05-30 | 2016-06-14 | Msd K.K. | Derivado de piperidina novedoso |
| US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
| EP1909576A4 (en) | 2005-07-29 | 2010-09-01 | Concert Pharmaceuticals Inc | NEW PHARMACEUTICAL COMPOUNDS |
| CA2617654A1 (en) * | 2005-08-04 | 2007-02-08 | Pfizer Limited | Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds |
| AU2006277253A1 (en) | 2005-08-10 | 2007-02-15 | Msd K.K. | Pyridone compound |
| EP2330125A3 (en) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| AU2006279680B2 (en) | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
| WO2007024004A1 (ja) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | フェニルピリドン誘導体 |
| AU2006288153A1 (en) | 2005-09-07 | 2007-03-15 | Msd K.K. | Bicyclic aromatic substituted pyridone derivative |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| CA2625877A1 (en) | 2005-10-18 | 2007-04-26 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| KR20080059233A (ko) | 2005-10-21 | 2008-06-26 | 노파르티스 아게 | 레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물 |
| WO2007049798A1 (ja) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | 新規ベンゾオキサチイン誘導体 |
| BRPI0618354B8 (pt) | 2005-11-10 | 2021-05-25 | Banyu Pharma Co Ltd | composto e seu uso, composição farmacêutica, preventivo ou remédio |
| CN101426782B (zh) * | 2006-02-23 | 2012-10-31 | 辉瑞股份有限公司 | 黑皮质素4型受体激动剂哌啶羰基吡咯烷 |
| ES2402581T3 (es) | 2006-02-23 | 2013-05-06 | Pfizer Limited | Piperidinoilpirrolidinas como agonistas del receptor de melanocortina tipo 4 |
| EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20090247560A1 (en) | 2006-09-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| WO2008120653A1 (ja) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | インドールジオン誘導体 |
| CN103601792B (zh) | 2007-06-04 | 2016-06-29 | 协同医药品公司 | 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂 |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| CA2700974A1 (en) * | 2007-10-04 | 2009-04-09 | Merck Sharp & Dohme Corp. | Substituted aryl sulfone derivatives as calcium channel blockers |
| WO2009110510A1 (ja) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | アルキルアミノピリジン誘導体 |
| CA2717384A1 (en) | 2008-03-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
| AU2009256157B2 (en) | 2008-06-04 | 2014-12-18 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US20110071129A1 (en) | 2008-06-19 | 2011-03-24 | Makoto Ando | Spirodiamine-diaryl ketoxime derivative |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| JPWO2010013595A1 (ja) | 2008-07-30 | 2012-01-12 | Ｍｓｄ株式会社 | ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体 |
| WO2010015972A1 (en) | 2008-08-06 | 2010-02-11 | Pfizer Limited | Diazepine and diazocane compounds as mc4 agonists |
| MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
| CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| UA99555C2 (en) | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
| EP2358200A4 (en) | 2008-11-17 | 2012-05-16 | Merck Sharp & Dohme | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES |
| WO2010069793A1 (en) * | 2008-12-16 | 2010-06-24 | F. Hoffmann-La Roche Ag | Process for the preparation of pyrollidine-3-carboxylic acids |
| US8324250B2 (en) * | 2009-03-19 | 2012-12-04 | Hoffmann-La Roche Inc. | Piperidine derivatives as NK3 receptor antagonists |
| WO2011011508A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
| US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
| CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
| WO2011137012A1 (en) | 2010-04-27 | 2011-11-03 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| WO2011156246A1 (en) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CA2825098C (en) | 2011-01-27 | 2020-03-10 | Universite De Montreal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
| SG192941A1 (en) | 2011-02-25 | 2013-09-30 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| KR20150036245A (ko) | 2012-08-02 | 2015-04-07 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 트리시클릭 화합물 |
| MX2015010935A (es) | 2013-02-22 | 2015-10-29 | Merck Sharp & Dohme | Compuestos biciclicos antidiabeticos. |
| EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| EP4424697A3 (en) | 2013-06-05 | 2024-12-25 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| JP6769963B2 (ja) | 2014-08-29 | 2020-10-14 | ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ | α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤 |
| US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
| US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
| AU2017342083A1 (en) | 2016-10-14 | 2019-04-11 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
| CA3119509A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxxylase |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0696919B1 (en) * | 1993-04-05 | 2002-01-30 | Competitive Technologies, Inc. | Diagnosis and treatment of erectile dysfunction |
| US6166037A (en) * | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
| AU9206798A (en) | 1997-08-28 | 1999-03-16 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
| CA2377369A1 (en) * | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| IL150849A0 (en) | 2000-02-11 | 2003-02-12 | Vertex Pharma | Piperzine and piperidine derivatives and pharmaceutical compositions containg the same |
| JP2003528088A (ja) * | 2000-03-23 | 2003-09-24 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作働薬としての置換ピペリジン類 |
| AU6497701A (en) * | 2000-05-30 | 2001-12-11 | Merck & Co Inc | Melanocortin receptor agonists |
| US6511994B2 (en) * | 2000-10-11 | 2003-01-28 | Merck & Co., Inc. | Modulators of CCR5 chemokine receptor activity |
| KR20030076716A (ko) * | 2001-02-28 | 2003-09-26 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 효능제로서 아실화 피페리딘 유도체 |
| CA2439119A1 (en) | 2001-02-28 | 2002-09-06 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
-
2002
- 2002-02-25 DE DE60215132T patent/DE60215132T2/de not_active Expired - Lifetime
- 2002-02-25 JP JP2002567901A patent/JP4323169B2/ja not_active Expired - Fee Related
- 2002-02-25 CA CA2439149A patent/CA2439149C/en not_active Expired - Fee Related
- 2002-02-25 AU AU2002255597A patent/AU2002255597B8/en not_active Ceased
- 2002-02-25 AT AT02725001T patent/ATE341327T1/de not_active IP Right Cessation
- 2002-02-25 US US10/468,515 patent/US7015235B2/en not_active Expired - Lifetime
- 2002-02-25 EP EP02725001A patent/EP1372653B1/en not_active Expired - Lifetime
- 2002-02-25 WO PCT/US2002/005623 patent/WO2002068387A2/en not_active Ceased
- 2002-02-25 ES ES02725001T patent/ES2272703T3/es not_active Expired - Lifetime
-
2005
- 2005-09-30 US US11/239,721 patent/US20060035935A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002068387A8 (en) | 2003-09-04 |
| EP1372653B1 (en) | 2006-10-04 |
| CA2439149A1 (en) | 2002-09-06 |
| WO2002068387A3 (en) | 2003-02-20 |
| JP2004527498A (ja) | 2004-09-09 |
| AU2002255597B8 (en) | 2006-10-26 |
| US7015235B2 (en) | 2006-03-21 |
| US20060035935A1 (en) | 2006-02-16 |
| EP1372653A2 (en) | 2004-01-02 |
| CA2439149C (en) | 2012-04-24 |
| JP4323169B2 (ja) | 2009-09-02 |
| DE60215132D1 (de) | 2006-11-16 |
| EP1372653A4 (en) | 2005-10-05 |
| ES2272703T3 (es) | 2007-05-01 |
| AU2002255597B2 (en) | 2006-03-02 |
| WO2002068387A2 (en) | 2002-09-06 |
| US20040097546A1 (en) | 2004-05-20 |
| ATE341327T1 (de) | 2006-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60215132T2 (de) | Acylierte piperidin-derivate als melanocortin-4-rezeptor-agonisten | |
| DE60219295T2 (de) | Acylierte piperidinderivate als melanocortin-4-rezeptoragonisten | |
| AU2002250343B2 (en) | Acylated piperidine derivatives as melanocortin-4 receptor agonists | |
| EP1411940B1 (en) | Bridged piperidine derivatives as melanocortin receptor agonists | |
| AU2002255597A1 (en) | Acylated piperidine derivatives as melanocortin-4 receptor agonists | |
| AU2002258414A1 (en) | Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists | |
| AU2002250343A1 (en) | Acylated piperidine derivatives as melanocortin-4 receptor agonists | |
| AU2002320494A1 (en) | Bridged piperidine derivatives as melanocortin receptor agonists | |
| US20040266821A1 (en) | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: MERCK & CO., INC., RAHWAY, N.J., US |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US |
|
| R081 | Change of applicant/patentee |
Ref document number: 1372653 Country of ref document: EP Owner name: SCHERING CORPORATION, US Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., 07065-0900 RAHWAY, US Effective date: 20121213 |
|
| R082 | Change of representative |
Ref document number: 1372653 Country of ref document: EP Representative=s name: ABITZ & PARTNER, DE Effective date: 20121213 |